drug

(ethinylestradiol + segesterone acetate) ER

Marketedupdated 2mo ago

by Mayne Pharma USA Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 1, 2039

~12.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Jun 21, 2039formulationUS 10918649
Jun 21, 2039formulationUS 10925882
Jun 21, 2039formulationUS 10940157
Jun 21, 2039formulationUS 11529308
Jun 21, 2039method-of-use (U-3785)US 11850251
Jun 21, 2039formulationUS 12303518
Feb 1, 2039method-of-use (U-2786)US 10632066
Feb 1, 2039method-of-use (U-2787)US 10765628
Feb 1, 2039method-of-use (U-2786)US 10780047

Data sources

ClinicalTrials.gov

last refreshed 26m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?